Eli Lilly, Weight Loss Pill
Eli Lilly wants to take big swings in Alzheimer's, ALS, chronic pain and other difficult diseases after its success in ...
Eli Lilly and Company (NYSE:LLY) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Shares of Eli Lilly and Company (NYSE:LLY – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-one brokerages that are presently covering the stock, ...
Pharmaceutical company Eli Lilly (LLY) has been raking it in lately thanks to its two flagship products: Mounjaro and Zepbound. These two have ...
Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving ...
Strategic Financial Concepts LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 67.7% during the fourth quarter, according to the company in its most recent filing ...
Eli Lilly 's blockbuster weight loss drugs, and questions about its valuation. Then, Ricky continues his conversation with ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results